zoledronic acid


Siam Bheasach


Siam Pharmaceutical
Concise Prescribing Info
Zoledronic acid monohydrate
Treatment of osteolytic, osteoblastic & mixed bone metastases of solid tumors & osteolytic lesions of multiple myeloma in conjunction w/ standard antineoplastic therapy. Treatment of hypercalcemia of malignancy (HCM). Reduction of bone damage in patients w/ advanced malignancies involving bone.
Dosage/Direction for Use
IV infusion of no <15 min. Adult & elderly Bone metastases & osteolytic lesions; bone damage in patients w/ advanced malignancies involving bone 4 mg every 3-4 wk. Administer oral Ca supplement 500 mg & vit D 400 IU daily. HCM 4 mg.
Hypersensitivity to bisphosphonates. Pregnancy & lactation, hypocalcemia.
Special Precautions
Severe renal impairment. Monitor serum Ca, phosphate, Mg & creatinine. Ensure adequate hydration. Avoid invasive dental procedures in patients w/ concomitant risk factors (eg, cancer, chemotherapy, corticosteroids, poor oral hygiene) due to risk of osteonecrosis of the jaw.
Adverse Reactions
Anemia, headache, conjunctivitis, nausea, vomiting, anorexia, bone pain, myalgia, arthralgia, renal impairment, fever, flu-like syndrome, hypophosphatemia, increased blood creatinine & blood urea, hypocalcemia, osteonecrosis of the jaw.
Drug Interactions
Aminoglycosides, other potentially nephrotoxic drugs, thalidomide. Must not be mixed w/ Ca or other divalent cation-containing infusion soln eg, lactated Ringer's soln. Should be administered as a single IV soln & in a line separate from all other drugs.
ATC Classification
M05BA08 - zoledronic acid ; Belongs to the class of bisphosphonates. Used in the treatment of bone diseases.
Zolennic infusion 4 mg/5 mL
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in